XML 61 R35.htm IDEA: XBRL DOCUMENT v3.22.0.1
The Company (Details)
12 Months Ended
Dec. 31, 2021
USD ($)
segment
product
Dec. 31, 2020
USD ($)
Oct. 31, 2020
USD ($)
Sep. 30, 2019
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Line Items]        
Number of operating segments | segment 1      
Number U.S. FDA approved products | product 2      
Upfront payment receivable $ 88,000,000      
Cash, cash equivalents and investments 139,801,000 $ 240,364,000    
Collaborative Arrangement        
Organization, Consolidation and Presentation of Financial Statements [Line Items]        
Supplemental upfront payment receivable 2,000,000      
Second Santen Agreement | Santen        
Organization, Consolidation and Presentation of Financial Statements [Line Items]        
Upfront payment receivable 88,000,000   $ 50,000,000  
Supplemental upfront payment receivable 2,000,000      
Convertible Senior Notes Due 2024 | Convertible debt        
Organization, Consolidation and Presentation of Financial Statements [Line Items]        
Principal amount $ 316,250,000 $ 316,250,000   $ 316,250,000
Debt instrument, interest rate percentage       1.50%